In the Asia Pacific region, Sarclisa combination regimens were also recently approved by the National Medical Products Administration in China, specifically Sarclisa-VRd in NDMM patients who are ...
In the Asia-Pacific region, Japan is currently reviewing a regulatory submission for the antibody in NDMM subjects who are not eligible for haematopoietic stem cell transplantation. Sarclisa has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback